Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy.

JAMA Oncol · 2026 · PMC12784257 · PMID 41505116

Europe PMC DOI

hedged sentences

0.3700

closest p · 7.4× alpha

0.3700

boldest claim

The sentences

a favorable trendP = .37not close (p > 0.1)

Although the associations with DSS and OS were not statistically significant, the point estimates suggested a favorable trend among those who used SGLT2 inhibitor (DSS: HR, 0.60; 95% CI, 0.20-1.85; P = .37; OS: HR, 0.70; 95% CI, 0.42-1.16; P = .17; Figure 1 C and D).

also in 1,335 other papers

did not reach statistical significanceno p-value reported

However, cancer-specific and overall survival did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.